Astrazeneca Plc · LSE:AZN
Astrazeneca — JP Morgan Healthcare Conference 2025
26 slides from Astrazeneca's conference presentation, Jan 14, 2025
Slide 1: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference Aradhana Sarin, EVP & CFO 14 January 2025
Slide 2: Forward looking statements
Forward looking statements In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Strong growth across focus therapy areas
Strong growth across focus therapy areas Strategic focus on 5 therapy areas Oncology BioPharmaceuticals Rare Disease $39.2bn 9M 2024 Total Revenue +19% vs. 9M 2023 Cardiovascular, Renal Respiratory & Vaccines & Immune $6.12 & Metabolism (CVRM) Immunology (R&I) Therapies (V&I) 9M 2024 Core EPS Strong
Slide 4: Broad-based, diversified global business
Broad-based, diversified global business +20% US share of Total Revenue to grow 9% +23% driven by portfolio of innovative medicines and launch of NMEs 21% +22% % Total 43% 16,703 China: 5,049 +15% Revenue +4% 8,240 13% Ex-China: 5,492 +30% 14% 3,698 Anticipate durable growth across US Emerging Europ
Slide 5: Pace of NME launches accelerating
Pace of NME launches accelerating 7 NMEs delivered to date with strong commercial momentum liver cancer HR+/HER2- mBC EVH in PNH ATTRv-PN asthma RSV COVID-19 21 NMEs in late-stage1 development, on track to deliver 20 by 2030 5 1. Late-stage defined as Phase IIb, registrational Phase II or III trials
Slide 6: Delivered 9 positive Phase III trials in 2024
Delivered 9 positive Phase III trials in 2024 LAURA | Stg III u/r NSCLC ADRIATIC | LS-SCLC Expanding Tagrisso as backbone TKI in Imfinzi first and only IO to show survival benefit in LS-SCLC early-stage NSCLC ECHO | MCL NIAGARA | MIBC Imfinzi first perioperative IO regimen to extend survival in Calq
Slide 7: Investing in disruptive technologies to drive 2030+ growth
Investing in disruptive technologies to drive 2030+ growth Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and Develop scalable cell Replace systemic Make cure possible lead in new Replace ex
Slide 8: Unprecedented pipeline momentum through 2025
Unprecedented pipeline momentum through 2025
Slide 9: Entering remarkably catalyst-rich 2025
Entering remarkably catalyst-rich 2025 Multiple indication expansion opportunities for existing medicines and first Phase III data for 7 NMEs Select Phase III data for existing medicines First Phase III data for NMEs Datroway | lung and breast cancer camizestrant SERENA-6 (HR+/HER2- mBC) ngSERD AVAN
Slide 10: Enhertu – significant new breast cancer indication opportunities
$5bn+* Enhertu – significant new breast cancer indication opportunities and continued strong demand in 2025 DESTINY-Breast06 moves Enhertu into CTx-naïve HER2-low and -ultralow 1L 2L 3L+ Enhertu HER2-low established SoC DESTINY-Breast061 — DESTINY-Breast06 FDA approval anticipated H1 2025 60-65% H1
Slide 11: Imfinzi – growth momentum to accelerate with multiple new indications in 2025
$5bn+* Imfinzi – growth momentum to accelerate with multiple new indication opportunities in 2025 Next-wave IO launches Advancing Imfinzi-based combinations Expand leadership + oleclumab (PACIFIC-8, 9) u/r NSCLC Lung | early-stage NSCLC and LS-SCLC + Datroway (AVANZAR) 1L NSCLC + ceralasertib (LATIF
Slide 12: R&I – Sustained growth momentum across COPD and asthma
R&I – Sustained growth momentum across COPD and asthma First Phase III biologic data in COPD anticipated in 2025 COPD est. 91m patients by 20301 Asthma est. 93m patients by 20301 — AirSupra — Breztri — Breztri Inhaled Inhaled — AZD8630 (iTSLP) — Phase III KALOS/LOGOS severe asthma | H1 2025 — Fasenr
Slide 13: First pivotal data for 7 NMEs and important Phase I/II data
First pivotal data for 7 NMEs and important Phase I/II data for several $5bn+ potential medicines in 2025 First Phase III NME data readouts in 2025 camizestrant SERENA-6 SERENA-6 anselamimab CAEL101-301/2 gefurulimab PREVAIL oral SERD (HR+/HER2- (HR+/HER2-mBC) mBC) AL depleter (AL-A) s.c. C5 mAb (gM
Slide 14: Datroway – TROPION-Breast02 and AVANZAR to expand use
$5bn+* Datroway – TROPION-Breast02 and AVANZAR to expand use into triple negative breast cancer and 1L NSCLC TROPION-Breast02 in TNBC | H1 2025 AVANZAR in 1L mNSCLC | H2 2025 Poor outcomes and high unmet need in PD-L1- mTNBC TROPION-Lung04 (Datroway + Imfinzi ± platinum CTx) triplet showed 77% ORR i
Slide 15: camizestrant – SERENA-6 read out in 2025
$5bn+* camizestrant – SERENA-6 read out in 2025 is first step toward establishing the new ET backbone in HR+/HER2- breast cancer Potential to transform 1L HR+ mBC landscape Established benefit in Phase II SERENA-21 with proactive and pre-emptive treatment regimens current standard of care clinical d
Slide 16: baxdrostat – BaxHTN first Phase III read out in 2025
$5bn+* baxdrostat – BaxHTN first Phase III read out in 2025 for multi-blockbuster potential medicine Novel treatment for hypertension Positive Phase IIb BrigHTN Robust Phase III programme hard-to-treat HTN placebo baxdrostat ~45m (uHTN and rHTN) impacts ~45m patients across G7 0.5mg 1mg 2mg BaxHTN e
Slide 17: eneboparatide – CALYPSO read out in 2025
$1–3bn* eneboparatide – CALYPSO read out in 2025 first Phase III data, expanding presence in rare endocrinology Potential best-in-class profile to Demonstrated benefit in Phase IIa trial on clinically important Ca2+ measures1 treat hypoparathyroidism Serum calcium (mean ADsCa, mg/dL) Mean oral calci
Slide 18: efzimfotase alfa – multi-blockbuster potential trial read out in 2025
$3–5bn* efzimfotase alfa – multi-blockbuster potential trial read out expected in 2025, building on Strensiq foundation efzimfotase alfa differentiated profile >6x addressable population vs Strensiq Strensiq | 9M 2024 $996m, +19% Strensiq Total Revenue ($m) — Phase III trials include broad HPP patie
Slide 19: Closing remarks
Closing remarks
Slide 20: Disciplined investment and portfolio prioritisation driving greater pipeline value
Disciplined investment and portfolio prioritisation driving greater pipeline value Growing number of late-stage1 trials with increasing average peak year revenue $m 95 1,200 91 91 late-stage trials1 ongoing with 90 84 1,000 average peak year revenue2 of >$1bn 85 81 80 77 800 75 600 70 65 400 R&D exp
Slide 21: Significant progress made in areas to drive 2030+ growth
Significant progress made in areas to drive 2030+ growth Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and Develop scalable cell Replace systemic Make cure possible lead in new Replace exis
Slide 22: On track to deliver on 2030 ambitions
On track to deliver on 2030 ambitions supported by strong momentum and catalyst-rich 2025 Ambition to deliver $80bn in On track to deliver mid-30s% Ambition to deliver at least 20 Total Revenue by 20301 Core operating margin by 2026 NMEs by 2030 Strong growth anticipated in 2025 Growth in SG&A slowe
Slide 23: Appendix
Appendix
Slide 24: Progressing key sustainability ambitions
Progressing key sustainability ambitions Reinforcing our commitment to driving change for people, society and the planet BIB BIB Ambition Zero BIB Ethics & P Health Equity P P Carbon Transparency Working to remove barriers Driving industry-leading Fostering a culture underpinned to healthcare climat
Slide 25: Glossary
Glossary 1L, 2L, 3L first-, second-, third-line ES-SCLC early stage small-cell lung cancer NF1-PN neurofibromatosis type 1-plexiform neurofibromas AAV adeno-associated virus ET endocrine therapy ngSERD next-generation oral selective estrogen receptor degrader ADC antibody conjugate EU Europe NME new
Slide 26: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis